European Commission Approves Bristol Myers Squibb's Opdivo (Nivolumab) In Combination With Cisplatin And Gemcitabine For The First-line Treatment Of Unresectable Or Metastatic Urothelial Carcinoma
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Bristol Myers Squibb's Opdivo (Nivolumab) in combination with Cisplatin and Gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This approval is based on the results from the CheckMate -901 Phase 3 trial, which demonstrated a survival benefit over standard-of-care chemotherapy alone.
May 29, 2024 | 11:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The European Commission has approved Bristol Myers Squibb's Opdivo in combination with Cisplatin and Gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This approval is based on the CheckMate -901 Phase 3 trial results, showing a survival benefit over standard chemotherapy.
The approval of Opdivo in combination with Cisplatin and Gemcitabine for a new indication in the European Union is a significant milestone for Bristol Myers Squibb. The CheckMate -901 trial demonstrated a survival benefit, which is likely to positively impact BMY's stock price in the short term due to the expanded market potential and positive clinical results.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100